South San Francisco, CA — February 18, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and…Original Article
FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
